Tissue Repair and Healing Peptides: Monographs

BPC-157, TB-500 and the blended products built from them dominate this category. The evidence base is overwhelmingly preclinical, and regulatory status is the practical constraint.

BPC-157, TB-500 and the blended products built from them dominate this category. The evidence base is overwhelmingly preclinical, and regulatory status is the practical constraint.

Peptides covered in this chapter

BPC-157, BPC-157, TB-500 (Blend), BPC-157, TB-500, GHK-Cu (Glow Blend), BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend), Pentadecapeptide, TB-500 (Thymosin Beta-4), TB-500 Fragment (17-23)

BPC-157

BPC-157 is a synthetic peptide studied for its potential in tissue repair and recovery.

Regulatory status

• BPC-157 is not FDA-approved for any indication in humans. There is no NDA, BLA, or approved IND that permits its clinical use in US patients.
• The FDA has classified BPC-157 as a Category 2 bulk drug substance, meaning it is explicitly prohibited from being compounded by licensed 503A or 503B pharmacies.
• “Research use only” is not a legal loophole. Products sold under this label cannot legally be administered to humans, and purchasing them for personal use carries real legal risk.

Dosing

• Commonly used doses are 200-500 mcg per injection , once or twice daily, but these figures come from clinical practice and vendor convention rather than from a dose-finding trial.
• Human evidence is thin, not absent. A 2025 review in Current Reviews in Musculoskeletal Medicine found only three pilot studies in humans, covering intraarticular knee pain, interstitial cystitis, and intravenous safety.
• BPC-157 is not an FDA-approved drug. It was placed in FDA Category 2 in 2023, removed in April 2026 after the nomination was withdrawn, and recommended for the 503A Bulks List by the FDA’s advisory committee in July 2026 — but that recommendation is non-binding and compounding is still not authorised.
• It is banned in sport. WADA added BPC-157 to its Prohibited List in 2022, so competitive athletes should treat any use as a positive test.

Common side effects

• BPC-157 is a synthetic peptide currently prohibited by the FDA for human use.
• Common side effects include nausea and dizziness, though data is limited.
• Serious side effects are rare but can include allergic reactions.

Results and timeline

• BPC-157 is currently prohibited by the FDA as a Category 2 substance, making it illegal for human therapeutic use despite ongoing research interest
• Most preclinical studies show tissue repair effects within 7-14 days, with peak benefits observed at 14-28 days in animal models
• No large-scale human clinical trials have established definitive efficacy or safety profiles for therapeutic applications

Cost and access

• BPC-157 is currently prohibited by the FDA under Category 2 bulk substance regulations, significantly limiting legal access and affecting pricing structures
• Monthly program costs range from $200-800 when available through licensed clinics, with consultation fees adding $150-400 initially
• Insurance coverage is extremely limited due to the peptide’s research status and FDA prohibition, making most treatments cash-pay only

Practical notes

• Reconstitution means dissolving lyophilized (freeze-dried) BPC-157 powder in a liquid diluent — typically bacteriostatic water (BAC water) — to create an injectable solution at a known concentration in mcg/mL.
• Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for BPC-157 because it inhibits microbial growth and allows multi-dose use over 14–28 days when refrigerated at 36–46°F (2–8°C).

Data points extracted from source articles: Reported dose figures: 250-500 mcg, 5 mg, 200-500 mcg, 250 mcg, 1,000 mcg · Routes mentioned: oral, subcutaneous, intravenous · Price points: $200, $150, $80, $350

BPC-157, TB-500 (Blend)

Patients may start noticing effects from BPC-157, TB-500 (Blend) therapy within 2 to 4 weeks, with more pronounced outcomes by 3 months.

Regulatory status

• The BPC-157, TB-500 blend is not FDA-approved for any indication and carries a “research use only” classification in the United States.
• Neither BPC-157 nor TB-500 (thymosin beta-4 fragment) is currently on the FDA’s list of bulk drug substances that may be used in compounding under 503A or 503B — meaning licensed compounding pharmacies generally cannot legally compound this blend for patient use.
• Selling this blend to humans as a therapeutic product — whether online, through a clinic, or via a compounding pharmacy — violates federal law governing unapproved new drugs.

Dosing

• Standard Dosage Range: Typically ranges from 200-500 mcg for BPC-157 and 2-5 mg for TB-500 per administration.
• Administration Method: Most commonly administered subcutaneously or intramuscularly.
• Typical Cycle Length: Often prescribed for 4-6 weeks, with cycles adjusted based on individual response.
• Regulatory Status: Not FDA-approved; available for research purposes only.

Common side effects

• BPC-157, TB-500 (Blend) is not FDA-approved and remains available for research purposes only, with limited human safety data
• Most documented side effects occur at injection sites, affecting approximately 15-25% of research subjects in preliminary studies
• The 15-amino acid BPC-157 peptide (molecular weight 1,419 Da) combined with the 43-amino acid TB-500 sequence creates potential for additive effects and interactions

Results and timeline

• Patients may start noticing effects from BPC-157, TB-500 (Blend) therapy within 2 to 4 weeks, with more pronounced outcomes by 3 months.
• Clinical data on this peptide blend is limited, focusing mainly on cellular repair and angiogenesis.
• Factors such as dosing compliance, diet, and exercise significantly influence results.

Cost and access

• BPC-157, TB-500 (Blend) costs range from $200-$800 monthly through research programs, with consultation fees adding $150-$400 initially
• Insurance does not cover research peptides, making this entirely out-of-pocket for patients participating in studies or research protocols
• Compounded versions from licensed pharmacies typically cost 30-50% less than pre-mixed research formulations at $200-$400 monthly

Data points extracted from source articles: Reported dose figures: 2-5 mg, 200-500 mcg, 2 mg, 3 mg, 250-500 mcg · Routes mentioned: subcutaneous, intramuscular, oral · Price points: $400, $200, $800, $300

BPC-157, TB-500, GHK-Cu (Glow Blend)

BPC-157, TB-500, and GHK-Cu (Glow Blend) are not FDA-approved and are available for research purposes only.

Dosing

• Standard Research Dosage: BPC-157 (250-500 mcg), TB-500 (2-5 mg), GHK-Cu (1-3 mg) administered subcutaneously 1-2 times daily for research protocols
• Administration Method: Subcutaneous injection using 29-31 gauge insulin syringes, rotating between abdomen, thigh, and upper arm injection sites
• Typical Research Cycle: 4-8 week protocols with 2-4 week washout periods between cycles in preclinical studies
• Half-Life Considerations: BPC-157 demonstrates 4-6 hour elimination half-life, TB-500 shows 2-3 day plasma stability, GHK-Cu exhibits 1-2 hour bioavailability window

Results and timeline

• BPC-157, TB-500, and GHK-Cu (Glow Blend) are not FDA-approved and are available for research purposes only.
• Clinical data is primarily preclinical, with limited human trials; expectations should be tempered.
• Many patients report initial effects within 1-2 weeks, but significant changes often require 3-6 months.

Data points extracted from source articles: Reported dose figures: 250-500 mcg, 1-2 mg, 2-5 mg, 1-3 mg, 2-3 mg · Routes mentioned: subcutaneous, oral, topical

BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend)

BPC-157, TB-500, KPV, and GHK-Cu 80mg (Klow Blend) are research peptides not approved by the FDA.

Regulatory status

• None of the four peptides in the Klow Blend — BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, or GHK-Cu — hold FDA approval for any human indication as of March 2026.
• The FDA classifies all four components as research-only substances, meaning their legal use in the US is restricted to properly supervised research settings under appropriate oversight.
• BPC-157 and TB-500 are explicitly listed on the FDA’s Category 2 bulk drug substances list, meaning licensed compounding pharmacies (503A and 503B) are prohibited from compounding them for patient use.

Dosing

• Standard Dosage Range: BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) is typically administered in microgram to milligram doses, depending on the specific peptide and use case.
• Administration Method: Commonly administered via subcutaneous injection, but other methods like oral and topical may apply based on peptide properties.
• Typical Cycle Length: Treatment cycles often range from 4 to 12 weeks, with variations based on therapeutic goals and patient response.
• Regulatory Status: Not FDA-approved; available for research purposes only.

Common side effects

• The BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) is not FDA-approved and available for research purposes only, with limited human safety data
• Individual component peptides show injection site reactions in 15-30% of research subjects, with BPC-157 demonstrating the highest local tolerability
• TB-500 (Thymosin Beta-4) carries potential cardiovascular monitoring requirements due to its 43-amino acid sequence and angiogenic properties

Results and timeline

• BPC-157, TB-500, KPV, and GHK-Cu 80mg (Klow Blend) are research peptides not approved by the FDA.
• Realistic timelines for noticing effects vary: initial changes may be observed within weeks, with more pronounced results over months.
• Factors like dosing compliance, diet, and exercise significantly impact outcomes.

Cost and access

• BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) is not FDA-approved and available for research purposes only, significantly limiting access and increasing costs
• Research-grade peptide blends typically cost $200-$800 per month through specialized research suppliers
• No insurance coverage exists for research peptides, making all costs out-of-pocket

Data points extracted from source articles: Reported dose figures: 80mg, 200-500 mcg, 250-500 mcg, 200-400 mcg, 2-4 mg · Routes mentioned: subcutaneous, oral, topical · Price points: $300, $200, $150, $800

Pentadecapeptide

Dosing

• Standard Dosage Range : Typically administered in micrograms (mcg) via subcutaneous injection.
• Administration Method : Primarily subcutaneous; specific technique and rotation are crucial for efficacy.
• Typical Cycle Length : Varies, often ranging from several weeks to months, depending on therapeutic goals.
• Regulatory Status : Currently under research; not FDA-approved for specific indications.

Data points extracted from source articles: Reported dose figures: 200-300 mcg, 250 mcg, 2 mg, 100 mcg · Routes mentioned: subcutaneous, intramuscular, oral

TB-500 (Thymosin Beta-4)

Dosing

• TB-500 (Thymosin Beta-4) is administered subcutaneously at typical research doses ranging from 2-10 mg per injection, 1-3 times weekly
• The peptide consists of a 43-amino acid sequence with the active region being the N-terminal acetylated 17-23 fragment (Ac-LKKTETQ)
• Standard research protocols utilize 4-6 week cycles with 2-4 week washout periods between cycles
• TB-500 (Thymosin Beta-4) has a plasma half-life of approximately 2-4 hours, requiring frequent dosing for sustained effects

Common side effects

• TB-500 (Thymosin Beta-4) is not FDA-approved and is available for research purposes only.
• Common side effects include localized irritation at the injection site and transient fatigue.
• Serious risks are not well-documented due to the lack of extensive human trials.

Cost and access

• TB-500 (Thymosin Beta-4) is not FDA-approved for human therapeutic use and is available for research purposes only, affecting all pricing considerations
• Research-grade TB-500 costs approximately $200-800 per month depending on dosing protocols and supplier quality standards
• No insurance coverage exists for TB-500 since it lacks FDA approval for any therapeutic indication

Data points extracted from source articles: Reported dose figures: 2 mg, 2-10 mg, 5 mg, 200-500 mcg · Routes mentioned: subcutaneous, oral, topical · Price points: $200, $100, $150, $15

TB-500 Fragment (17-23)

Regulatory status

• TB-500 Fragment (17-23) is not FDA-approved for any indication and is classified as “research use only” under current federal regulatory standards.
• Compounding pharmacies cannot legally produce TB-500 Fragment (17-23) for human use; it does not appear on the FDA’s 503A or 503B bulk drug substance lists as an approved compoundable agent.
• “Research use only” is not a legal loophole — purchasing or possessing this peptide under that label for personal human use exists in a legal grey zone with real enforcement risk.

Dosing

• TB-500 Fragment (17-23) is not FDA-approved and remains available for research purposes only, with no established clinical dosing guidelines
• Research protocols typically utilize doses ranging from 2-10 mg administered subcutaneously 2-3 times per week
• The fragment consists of a 7-amino acid sequence (Ac-LKKTETQ) with a molecular weight of 858.02 Da
• Administration requires subcutaneous injection using 29-31 gauge insulin needles with proper injection site rotation

Common side effects

• TB-500 Fragment (17-23) contains the N-terminal acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ) with a molecular weight of 831.98 Da
• The peptide is not FDA-approved and remains available only for research purposes, limiting comprehensive human safety data
• Most documented adverse events relate to injection site reactions, with frequency data primarily derived from animal studies and limited human case reports

Data points extracted from source articles: Reported dose figures: 2-10 mg, 5-10 mg, 2-3 mg, 2-5 mg, 2-8 mg · Routes mentioned: subcutaneous, intramuscular, oral

---

This article is part of the Peptide Therapy Complete Guide

• Chapter 1. What Is Peptide Therapy? A Plain-English Foundation
• Chapter 2. How Peptides Work: Mechanisms of Action by Class
• Chapter 3. Is Peptide Therapy Safe? Side Effects, Interactions and Long-Term Data
• Chapter 4. The Legal and Regulatory Landscape for Peptides in the United States
• Chapter 5. FDA Compounding Decisions and the 2026 Peptide Rulemaking
• Chapter 6. Dosing Principles: How Peptide Protocols Are Actually Built
• Chapter 7. Side Effects Across Peptides: Patterns, Routes and Management
• Chapter 8. What Results to Expect, and When
• Chapter 9. Cost, Insurance and Access: What Peptide Therapy Actually Costs
• Chapter 10. Reconstitution, Administration and Handling
• Chapter 11. How to Choose a Peptide Therapy Clinic
• Chapter 12. Telehealth Peptide Therapy: How Remote Access Works
• Chapter 13. Clinical Protocols and Stacks
• Chapter 14. Weight Loss and Metabolic Peptides: Monographs
• Chapter 15. Growth Hormone and Performance Peptides: Monographs
• Chapter 16. Tissue Repair and Healing Peptides: Monographs (you are here)
• Chapter 17. Longevity and Anti-Aging Peptides: Monographs
• Chapter 18. Cognitive, Mood and Sleep Peptides: Monographs
• Chapter 19. Skin, Hair and Aesthetic Peptides: Monographs
• Chapter 20. Sexual Health and Hormone Peptides: Monographs
• Chapter 21. Immune and Inflammatory Peptides: Monographs
• Chapter 22. Industry, Market and Research Developments

Previous: Chapter 15. Growth Hormone and Performance Peptides: Monographs

Next: Chapter 17. Longevity and Anti-Aging Peptides: Monographs